Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dry eye in hemifacial spasm patients before and after treatment with botulinum toxin type A
TCTR20130627001Recruiting
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Jun 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of botulinum toxin type A in hemifacial spasm (HFS) and dry eye syndrome (DED), sponsored by Ratchadaphiseksomphot Endowment Fund. Primary endpoint: Change in dry eye parameters after botulinum toxin type A treatment. Started Jun 2013; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
hemifacial spasm (HFS)dry eye syndrome (DED)
Beyond the preview
Go deeper on TCTR20130627001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20130627001.